Patient-reported outcomes (PROs) from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC)

被引：5

作者：

Powles, T. B. ^{[1
]}

Kopyltsov, E. ^{[2
]}

Su, P-J. ^{[3
]}

Parnis, F. X. ^{[4
]}

Park, S. H. ^{[5
]}

Yamamoto, Y. ^{[6
]}

Fong, P. C. ^{[7
,8
]}

Tournigand, C. ^{[9
]}

Duran, M. A. Climent ^{[10
]}

Bamias, A. ^{[11
]}

Caserta, C. ^{[12
]}

Chang, J. ^{[13
]}

Yan, E. ^{[14
]}

di Pietro, A. ^{[15
]}

Wang, J. ^{[16
]}

Grivas, P. ^{[17
]}

机构：

[1] Queen Mary Univ London, St Bartholomews Hosp, Expt Canc Med Ctr, Dept Med Oncol,Barts Canc Inst, London, England

[2] State Inst Healthcare Reg Clin Oncol Dispensary, Dept Med Oncol, Omsk, Russia

[3] Chang Gung Mem Hosp, Dept Oncol, Linkuo, Taiwan

[4] Univ Adelaide, Dept Med Oncol, Adelaide Canc Ctr, Adelaide, SA, Australia

[5] Sungkyunkwan Univ, Div Hematol Oncol, Dept Internal Med, Samsung Med Ctr, Seoul, South Korea

[6] Yamaguchi Univ, Dept Urol, Ube, Yamaguchi, Japan

[7] Univ Auckland, Dept Med Oncol, Auckland, New Zealand

[8] Auckland City Hosp, Auckland, New Zealand

[9] Paris Est Creteil Univ, Hop Henri Mondor, AP HP, Dept Med Oncol, Creteil, France

[10] Inst Valenciano Oncol, Dept Med Oncol, Valencia, Spain

[11] Natl & Kapodistrian Univ Athens, Sch Med, Dept Internal Med, Alexandra Gen Hosp, Athens, Greece

[12] Azienda Osped S Maria, Med Oncol Unit, Terni, Italy

[13] Pfizer, Global HEOR, New York, NY USA

[14] Pfizer, Biostat, La Jolla, CA USA

[15] Pfizer SRL, Immunooncol, Milan, Italy

[16] Pfizer, Biostat, Cambridge, MA USA

[17] Univ Washington, Div Med Oncol, Dept Med, Fred Hutchinson Canc Res Ctr, Seattle, MA USA

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.817

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

745P

引用

页码：S578 / S579

页数：2